JP2002517245A - 治療的および診断的ドメイン1β2GPIポリペプチドおよびその使用の方法 - Google Patents

治療的および診断的ドメイン1β2GPIポリペプチドおよびその使用の方法

Info

Publication number
JP2002517245A
JP2002517245A JP2000553585A JP2000553585A JP2002517245A JP 2002517245 A JP2002517245 A JP 2002517245A JP 2000553585 A JP2000553585 A JP 2000553585A JP 2000553585 A JP2000553585 A JP 2000553585A JP 2002517245 A JP2002517245 A JP 2002517245A
Authority
JP
Japan
Prior art keywords
gpi
polypeptide
domain
antibody
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000553585A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002517245A5 (cg-RX-API-DMAC7.html
Inventor
デイビッド エム. マルキス,
ギルバート エム. アイバーソン,
エドワード ジェイ. ビクトリア,
デイビッド エス. ジョーンズ,
マシュー ディー. リニック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Jolla Pharmaceutical Co
Original Assignee
La Jolla Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27376031&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2002517245(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by La Jolla Pharmaceutical Co filed Critical La Jolla Pharmaceutical Co
Publication of JP2002517245A publication Critical patent/JP2002517245A/ja
Publication of JP2002517245A5 publication Critical patent/JP2002517245A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000553585A 1998-06-09 1999-06-09 治療的および診断的ドメイン1β2GPIポリペプチドおよびその使用の方法 Pending JP2002517245A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8865698P 1998-06-09 1998-06-09
US60/088,656 1998-06-09
US10308898P 1998-10-05 1998-10-05
US60/103,088 1998-10-05
US09/328,199 US6858210B1 (en) 1998-06-09 1999-06-08 Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US09/328,199 1999-06-08
PCT/US1999/013194 WO1999064595A1 (en) 1998-06-09 1999-06-09 THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 β2GPI POLYPEPTIDES AND METHODS OF USING SAME

Publications (2)

Publication Number Publication Date
JP2002517245A true JP2002517245A (ja) 2002-06-18
JP2002517245A5 JP2002517245A5 (cg-RX-API-DMAC7.html) 2006-08-03

Family

ID=27376031

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000553585A Pending JP2002517245A (ja) 1998-06-09 1999-06-09 治療的および診断的ドメイン1β2GPIポリペプチドおよびその使用の方法

Country Status (12)

Country Link
US (2) US6858210B1 (cg-RX-API-DMAC7.html)
EP (1) EP1092027B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002517245A (cg-RX-API-DMAC7.html)
KR (1) KR20010052713A (cg-RX-API-DMAC7.html)
CN (1) CN1310759A (cg-RX-API-DMAC7.html)
AT (1) ATE346922T1 (cg-RX-API-DMAC7.html)
AU (1) AU772851B2 (cg-RX-API-DMAC7.html)
CA (1) CA2329942A1 (cg-RX-API-DMAC7.html)
DE (1) DE69934228T2 (cg-RX-API-DMAC7.html)
ES (1) ES2275348T3 (cg-RX-API-DMAC7.html)
PT (1) PT1092027E (cg-RX-API-DMAC7.html)
WO (1) WO1999064595A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006507232A (ja) * 2002-07-19 2006-03-02 ザ ジェネラル ホスピタル コーポレイション オキシム結合体、およびそれらの形成および用途
JP2007535468A (ja) * 2003-03-07 2007-12-06 カーテーベー トゥモーアフォルシュングス ゲゼルシャフト ミット ベシュレンクテル ハフツング タンパク質結合性のドキソルビシン−ペプチド−誘導体
JP2025532422A (ja) * 2022-10-10 2025-09-29 深▲せん▼市迪克曼生物科技有限公司 新規なセラミド、その調製方法及び使用

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268454A (en) * 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
CA2376057A1 (en) * 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
EP1210124A2 (en) * 1999-07-29 2002-06-05 Epix Medical, Inc. Targeting multimeric imaging agents through multilocus binding
CN1399562A (zh) 1999-11-28 2003-02-26 拉卓拉药物公司 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物
CA2414076A1 (en) * 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
AU2002229639A1 (en) * 2000-12-13 2002-06-24 De Haard, Johannes Joseph Wilhelmus Camelidae antibody arrays
TWI221406B (en) 2001-07-30 2004-10-01 Epix Medical Inc Systems and methods for targeted magnetic resonance imaging of the vascular system
US20030114405A1 (en) * 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
AU2003303524A1 (en) * 2002-12-27 2004-07-29 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
WO2004089422A2 (en) * 2003-03-30 2004-10-21 La Jolla Pharmaceutical Co. Methods of treating and monitoring systemic lupus erythematosus in individuals
CA2591914C (en) * 2005-01-24 2017-04-25 Board Of Regents, The University Of Texas System Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
JP4898785B2 (ja) * 2005-04-18 2012-03-21 バイオ−ラッド ラボラトリーズ,インコーポレイティド リン脂質及び補因子タンパク質の共有結合による固相固定化
WO2008036449A2 (en) * 2006-06-29 2008-03-27 The Regents Of The University Of California Chemical antibodies for immunotherapy and imaging
US20080015145A1 (en) * 2006-07-11 2008-01-17 Maria Gyongyossy-Issa Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions
JP5461581B2 (ja) * 2009-01-02 2014-04-02 フライサン ディベロップメント カンパニー リミテッド 自己免疫疾患を診断するための合成ペプチド、方法およびキット
WO2011163568A1 (en) * 2010-06-24 2011-12-29 University Of Kansas Conjugates comprising an n-oxime bond and associated methods
CN105273080A (zh) * 2014-07-14 2016-01-27 于珮 一种还原型β2-糖蛋白Ⅰ的制备方法
US10098960B2 (en) 2015-04-03 2018-10-16 Ucl Business Plc Polymer conjugate
TWI572617B (zh) * 2016-01-20 2017-03-01 國立陽明大學 重組β-醣蛋白胜肽及其於抗腫瘤之應用
CN105801694A (zh) * 2016-05-03 2016-07-27 上海科新生物技术股份有限公司 一种抗心磷脂/β2糖蛋白I复合物的嵌合抗体
WO2019028336A1 (en) * 2017-08-03 2019-02-07 The Cleveland Clinic Foundation IMPROVED PEPTIDE EXPRESSION AND ANTIBODY DETECTION OF APO-H SPECIFIC SUBJECT
WO2022195051A1 (en) * 2021-03-18 2022-09-22 Université De Genève Peptides and use thereof for diagnosing and treating antiphospholipid syndrome

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191668A (en) 1977-02-03 1980-03-04 Scripps Clinic And Research Foundation Induction of immunological tolerance
US5126131A (en) 1983-01-24 1992-06-30 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
US5370871A (en) 1983-01-24 1994-12-06 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US6022544A (en) 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US4650675A (en) 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US4751181A (en) 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
EP0229108B1 (en) 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
ATE134880T1 (de) 1988-04-04 1996-03-15 Lawrence A Potempa Bindung von immunkomplexen durch modifizierte formen von c-reaktiven proteinen
CA2044142A1 (en) 1989-10-19 1991-04-20 Eiji Matsuura Carrier for binding of anti-phospholipid antibodies, an immunoassay method using the same and a kit therefor
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5162515A (en) 1990-01-16 1992-11-10 La Jolla Pharmaceutical Company Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5498538A (en) 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
CA2058769C (en) 1990-04-06 1999-03-02 Steven Anthony Krilis Methods for determining phospholipids and antibodies thereof
CA2098281A1 (en) 1990-12-17 1992-06-18 Howard M. Dintzis Suppression of immune responses of oligomeric forms of antigen of controlled chemistry
IE922292A1 (en) 1991-07-15 1993-01-27 Jolla Pharma Modified phosphorous intermediates for providing functional¹groups on the 5' end of oligonucleotides
EP0600088B1 (en) 1992-02-05 1998-12-30 Yamasa Corporation Solid-phase reagent and assay of antibody using the same
FR2701263B1 (fr) 1993-02-09 1995-04-21 Elie Stefas Procédé d'obtention d'une composition aqueuse protéinique, composition correspondante, glycoprotéine contenue et son utilisation pour la stabilisation de l'albumine et la détection ou le dosage d'anticorps.
EP1808183A3 (en) 1993-09-08 2009-07-01 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
WO1995014231A1 (en) 1993-11-16 1995-05-26 Yamasa Corporation Method of assaying antiphospholipid antibody and kit therefor
FR2722991B1 (fr) 1994-08-01 1996-10-11 Orstom Utilisation de la beta2-glycoproteine i sous au moins une de ses formes comme agent anti-infectueux et composition pharmaceutique corrrespondante
JPH08333390A (ja) 1995-04-07 1996-12-17 Hoechst Japan Ltd ペプチド及びそれからなる自己免疫疾患治療剤
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US5780319A (en) 1996-04-19 1998-07-14 Pasteur Sanofi Diagnostics Immunoassays to detect antiphospholipid antibodies
EP0954531A1 (en) 1996-06-06 1999-11-10 Lajolla Pharmaceutical Company aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES
DE19637770A1 (de) 1996-09-16 1998-03-19 Koenig & Bauer Albert Ag Verfahren und Anlage zum automatischen Zu- und Abführen von Rollen
ATE262539T1 (de) 1996-11-12 2004-04-15 Hope City Immunoreaktive peptid ctl epitope von menschlichem cytomegalovirus
GB9805477D0 (en) 1998-03-13 1998-05-13 Oxford Glycosciences Limited Methods and compositions for diagnosis of rheumatoid arthritis
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
IL125262A0 (en) 1998-07-07 1999-03-12 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
IL126447A (en) 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
CA2373016A1 (en) 1999-05-04 2000-11-09 Genethor Gmbh Method for diminishing specific immune reactions
CA2376057A1 (en) 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
AUPQ272699A0 (en) 1999-09-09 1999-09-30 Unisearch Limited Use of beta2GPI in diagnostic tests for autoimmune diseases
CN1399562A (zh) 1999-11-28 2003-02-26 拉卓拉药物公司 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物
US20010051351A1 (en) 2000-03-27 2001-12-13 Racis Stanley Paul Antigen-specific immune complex-based enzyme-linked immunosorbent assay
US20020150898A1 (en) 2000-04-18 2002-10-17 Tang Y. Tom Novel nucleic acids and polypeptides
AU2001263006A1 (en) 2000-05-18 2001-11-26 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2414076A1 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
DE10048417A1 (de) 2000-09-29 2002-04-11 Roche Diagnostics Gmbh Verbindungen mit verzweigtem Linker

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006507232A (ja) * 2002-07-19 2006-03-02 ザ ジェネラル ホスピタル コーポレイション オキシム結合体、およびそれらの形成および用途
JP2011105773A (ja) * 2002-07-19 2011-06-02 General Hospital Corp オキシム結合体、およびそれらの形成および使用のための方法
JP2007535468A (ja) * 2003-03-07 2007-12-06 カーテーベー トゥモーアフォルシュングス ゲゼルシャフト ミット ベシュレンクテル ハフツング タンパク質結合性のドキソルビシン−ペプチド−誘導体
JP2025532422A (ja) * 2022-10-10 2025-09-29 深▲せん▼市迪克曼生物科技有限公司 新規なセラミド、その調製方法及び使用
JP7818877B2 (ja) 2022-10-10 2026-02-24 深▲せん▼市迪克曼生物科技有限公司 新規なセラミド、その調製方法及び使用

Also Published As

Publication number Publication date
AU4339599A (en) 1999-12-30
WO1999064595A1 (en) 1999-12-16
AU772851B2 (en) 2004-05-06
DE69934228D1 (de) 2007-01-11
PT1092027E (pt) 2007-02-28
US20050004351A1 (en) 2005-01-06
US6858210B1 (en) 2005-02-22
DE69934228T2 (de) 2007-10-04
ATE346922T1 (de) 2006-12-15
EP1092027B1 (en) 2006-11-29
CA2329942A1 (en) 1999-12-16
WO1999064595A9 (en) 2000-09-08
KR20010052713A (ko) 2001-06-25
EP1092027A1 (en) 2001-04-18
CN1310759A (zh) 2001-08-29
ES2275348T3 (es) 2007-06-01

Similar Documents

Publication Publication Date Title
US6858210B1 (en) Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US6207160B1 (en) aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies
KR20000016414A (ko) Apl 면역반응성 펩티드, 그것의 콘주게이트 및 apl항체-매개병변의 치료방법
WO1996040197A9 (en) aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES
WO1997046251A9 (en) aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES
US7517657B2 (en) Peptides for detecting anti-double stranded DNA antibody and uses thereof
US8828942B2 (en) Means for treating synucleinopathies
US6410775B1 (en) APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US6455244B1 (en) Methods for the detection of antibodies associated with autoimmune disorders and infectious agents employing immunoretroid peptides derived from antigens associated with said disorders and agents
JPH02479A (ja) snRNP−A抗原及びそのフラグメント
US6825319B1 (en) Synthetic peptides and pharmaceutical compositions comprising them for diagnosis and treatment of anti-phospholipid syndrome
JP2003503040A (ja) 合成ペプチド免疫原およびそれに対する抗体
US5837686A (en) Peptides and antibodies for treatment of rheumatoid arthritis
AU2004201699A1 (en) Therapeutic and diagnostic domain 1 Beta2GPI polypeptides and methods of using same
JPH01199996A (ja) ペプチドおよびその製法
MXPA00012040A (en) THERAPEUTIC AND DIAGNOSTIC DOMAIN 1&bgr;2
JPH08333393A (ja) リポタンパク(a)の診断アッセイおよびそれに用いるペプチド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090625

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091117